BONE BIOLOGICS CORPORATION (OTCMKTS:BBLG) Files An 8-K Changes in Registrant’s Certifying Accountant

BONE BIOLOGICS CORPORATION (OTCMKTS:BBLG) Files An 8-K Changes in Registrant’s Certifying Accountant
Item 4.01 Changes in Registrant’s Certifying Accountant

Story continues below

Effective December 6, 2017, Anton & Chia, LLP (“Anton”) was dismissed as the independent accountant of the Company. On July 14, 2017, the Board of Directors acting on the recommendation of the Company’s Audit Committee approved the dismissal of Anton to occur at any time commencing the third quarter of the Company’s fiscal year.

Anton’s reports on the Company’s financial statements for the years ended December 31, 2015 and 2016 did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles except that the report for both years indicated that the Company’s ability to continue as a going concern is dependent upon its ability to secure additional sources of financing. Accordingly, such report indicated that there was substantial doubt as to the Company’s ability to continue as a going concern and that the financial statements did not include any adjustments relating to the recoverability and classification of asset carrying amounts on the amount and classification of liabilities that might result from the outcome of this uncertainty.

During the years ended December 31, 2015 and 2016 and through December 6, 2017, (i) there were no disagreements with Anton on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Anton, would have caused it to make reference thereto in connection with its reports on the financial statements for such years and (ii) there were no matters that were either the subject of a disagreement as defined in Item 304(a)(1)(iv) of Regulation S-K or a reportable event as described in Item 304(a)(1)(v) of Regulation S-K.

The Company provided Anton with a copy of the foregoing disclosures and requested Anton to furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether or not Anton agrees with the disclosures.

Effective December 7, 2017, the Company’s Board of Directors engaged Weinberg & Company, P.A. (“Weinberg”) as the Company’s new independent accountant to act as the principal accountant to audit the Company’s financial statements. The engagement of Weinberg was approved by the Board of Directors on July 14, 2017 on the recommendation of the Company’s Audit Committee to occur at any time commencing the third quarter of the Company’s final year. During the Company’s fiscal years ended December 31, 2015 and 2016 and through December 7, 2017, neither the Company, nor anyone acting on its behalf, consulted with Weinberg regarding either (i) the application of accounting principles to a specific completed or proposed transaction or the type of audit opinion that might be rendered on the Company’s financial statements, and no written report or oral advice was provided that Weinberg concluded was an important factor considered by the Company in reaching a decision as to any such accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) or a reportable event (as defined in Item 304(a)(1)(v) of Regulation S-K).


About BONE BIOLOGICS CORPORATION (OTCMKTS:BBLG)

Bone Biologics Corporation is a biotechnology company. The Company is focused on bone regeneration in spinal fusion using the recombinant human protein, known as NELL-1/DBX. The NELL-1/DBX combination product is an osteoinductive recombinant protein that provides target specific control over bone regeneration. The Company’s platform technology has application in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology and sports medicine. The Company’s platform technology is UCB-1, a skeletal specific growth factor used in combination with DBX, a demineralized bone matrix from Musculoskeletal Transplant Foundation (MTF). Together, with DBX, or alone, NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The NELL-1/DBX Fusion Device will consist of a single dose vial of NELL-1 recombinant protein freeze dried onto DBX.

An ad to help with our costs